Beeken Biomedical

Executive Summary

Beeken Biomedical, founded in 2015 and headquartered in Austin, Texas, is a private medical device company focused on advanced hemostatic solutions. Its flagship product, NuStat®, is an advanced hemostatic surgical dressing indicated for the temporary control of internal organ space bleeding in patients with Class III or IV hemorrhage, as well as severe surgical and traumatic wounds. The company operates in the orthopedic and surgical bleeding control markets, addressing a critical need in trauma and surgical settings. Despite limited public information, Beeken Biomedical's technology targets a significant unmet medical need, and its product has received FDA clearance for specific indications. The company's progress in commercialization and potential expansion of indications or partnerships presents opportunities for growth. However, as a private entity, detailed financials and pipeline data are not publicly available, making assessment challenging. The company appears to be at an early stage of commercialization, with potential for value creation through regulatory advancements and strategic collaborations.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for expanded indications (e.g., neurosurgery or cardiothoracic)45% success
• Q4 2026Strategic partnership or distribution agreement with a major medical device company50% success
• Q2 2026Series B or later funding round to scale commercial operations60% success